Pharvaris Reports First Quarter 2025 Financial Results and Provides Business Update

Enrollment underway in CHAPTER-3, a pivotal Phase 3 study of deucrictibant for prophylaxis of HAE attacks; topline data expected in 2H2026Attack dataset continues to accumulate in RAPIDe-3, a pivotal Phase 3 study of deucrictibant for the on-demand treatment of HAE attacks, strengthening confidence in clinical timelinesTQT study waivers received from FDA for both deucrictibant extended-release formulation and deucrictibant immediate-release formulationPharvaris Management to host R&D call on June 4 at 8:00 ...